Serum levels of high mobility group box 1 correlate with disease severity in recessive dystrophic epidermolysis bullosa

In the inherited blistering skin disease, recessive dystrophic epidermolysis bullosa (RDEB), there is clinical heterogeneity with variable scarring and susceptibility to malignancy. Currently, however, there are few biochemical markers of tissue inflammation or disease progression. We assessed whether the non‐histone nuclear protein, high mobility group box 1 (HMGB1), which is released from necrotic cells (including keratinocytes in blister roofs), might be elevated in RDEB and whether this correlates with disease severity. We measured serum HMGB1 by ELISA in 26 RDEB individuals (median 21.0 ng/ml, range 3.6–54.9 ng/ml) and 23 healthy controls (median 3.6, range 3.4–5.9 ng/ml) and scored RDEB severity using the Birmingham Epidermolysis Bullosa Severity Score (BEBSS; mean 34/100, range 8–82). There was a positive relationship between the BEBSS and HMGB1 levels (r = 0.54, P = 0.004). This study indicates that serum HMGB1 levels may represent a new biomarker reflecting disease severity in RDEB.

[1]  T. Ghaly,et al.  HMGB1 in renal ischemic injury. , 2012, American journal of physiology. Renal physiology.

[2]  A. Coyle,et al.  HMGB1 and RAGE in inflammation and cancer. , 2010, Annual review of immunology.

[3]  K. Tamai,et al.  Japanese guidelines for diagnosis and treatment of junctional and dystrophic epidermolysis bullosa , 2003, Archives of Dermatological Research.

[4]  C. Moss,et al.  The Birmingham Epidermolysis Bullosa Severity score: development and validation , 2009, The British journal of dermatology.

[5]  M. Churchill,et al.  The high mobility group box: the ultimate utility player of a cell. , 2012, Trends in biochemical sciences.

[6]  E. Bauer,et al.  The classification of inherited epidermolysis bullosa (EB): Report of the Third International Consensus Meeting on Diagnosis and Classification of EB. , 2008, Journal of the American Academy of Dermatology.

[7]  D. Murrell,et al.  Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa , 2008, Experimental dermatology.

[8]  Y. Kaneda,et al.  PDGFRα-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia , 2011, Proceedings of the National Academy of Sciences.

[9]  M. Bianchi,et al.  High‐mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity , 2007, Immunological reviews.

[10]  M. Aria,et al.  Epidermolysis Bullosa Oropharyngeal Severity (EBOS) score: a multicenter development and reliability assessment. , 2013, Journal of the American Academy of Dermatology.

[11]  J. Mellerio,et al.  Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. , 2009, Journal of the American Academy of Dermatology.

[12]  M. Tohyama,et al.  High-mobility group box 1 protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome. , 2011, Archives of dermatology.

[13]  J. Mellerio,et al.  Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. , 2009, Journal of the American Academy of Dermatology.

[14]  J. Uitto,et al.  Type VII collagen: the anchoring fibril protein at fault in dystrophic epidermolysis bullosa. , 2010, Dermatologic clinics.

[15]  J. Wagner,et al.  Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls , 2012, Experimental dermatology.